The Team
NIB biotec was founded as a spin-off of the University of Torino (Italy), bringing together years of expertise in oncology research and analytical chemistry with the goal of transforming scientific innovation into practical solutions for patients and healthcare professionals.
Throughout its growth journey, the company has received numerous national and international awards and recognitions, validating the strength of its scientific and entrepreneurial approach. This path has been built on science, innovation, social impact, and a commitment to making cancer diagnostics more accessible and timely.
Today, NIB biotec is developing ZenPSA-Pro, its flagship product: a rapid professional-use test based on proprietary urinary biomarkers for the early detection of prostate cancer. This innovative technology, already tested in more than 1,000 men with an indication for prostate biopsy, is designed to support the diagnostic process through a simple, non-invasive, and precision medicine-oriented approach.
As it prepares for the upcoming clinical study required for CE marking, NIB biotec is taking another important step toward bringing to market a solution aimed at improving the diagnostic pathway for prostate cancer, one of the most common cancers affecting the male population worldwide.
